Datavault AI (NASDAQ: DVLT) announced Tuesday an expanded definitive licensing agreement with DataMeds AI Inc., extending its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement aims to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments.
Under the revised terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization. The companies stated that the agreement accelerates the deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
The expanded relationship leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring. This positions Datavault AI to integrate its Web 3.0 and high-performance computing capabilities into healthcare, a sector increasingly focused on data interoperability and patient ownership of health information.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports and entertainment, biotech, education, fintech, real estate, energy, and healthcare. Its Data Science division leverages Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. The company’s Information Data Exchange enables digital twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity.
The news underscores a growing trend of blockchain and AI technologies entering healthcare data management, where patients increasingly seek control over their medical records and the ability to monetize their data. By integrating its technology into DataMEDS’ platform, Datavault AI aims to capture a share of the health and wellness market, which continues to expand as consumers invest in wearable devices and remote monitoring solutions.
For more details on the press release, visit https://ibn.fm/vBAxH. Further information about Datavault AI is available at https://dvlt.ai, and the latest news regarding DVLT can be found in the company’s newsroom at https://ibn.fm/DVLT.
